Disease resistance is affected by temperature. A rice gene, , is known to have conferred sustained resistance to (RSV) despite global warming. protects plants from growth stunting caused by RSV. The underlying resistance mechanism is unclear. Here, showed stable RSV resistance for 20 years in laboratory experiments. This gene encodes a protein distinct from well-studied plant disease-resistance proteins. It has a domain homologous to the histidine kinase/heat-shock protein 90-like ATPase superfamily. Rice has three paralogous genes including . The genes are expressed mainly in meristematic tissues. In the initial period after viral inoculation, RSV multiplication enhanced , whereas suppressed RSV multiplication. silencing inhibited plant growth regardless of viral infection, and silencing of the other paralogous gene that located closely to caused morphological abnormalities. The results suggested that the and its paralogs are related to plant development; especially, supports meristem growth, resulting in plant growth stabilizing. Growth stunting in the -silenced plants was more severe under repetitive heat stress, suggesting that contributed to the attenuation of heat damage in plant development. The symptoms of RSV infection (chlorosis, wilting, stunting, fewer tillers, and defective panicles) were similar to those of heat damage, suggesting that RSV multiplication induces heat-like stress in meristematic cells. Our findings suggest that the mechanism of meristem growth protection conferred by allows plants to withstand both heat stress and RSV multiplication. The suppression of RSV multiplication by the function in meristems results in durable resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225774 | PMC |
| http://dx.doi.org/10.3389/fpls.2020.00519 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antagonism of BST2/Tetherin, a new restriction factor of respiratory syncytial virus, requires the viral NS1 protein.
PLoS Pathog
November 2024
Université Paris-Saclay, Université de Versailles St. Quentin, M3P, UMR 1173, INSERM, Versailles, France.
Human respiratory syncytial virus (RSV) is an enveloped RNA virus and the leading viral agent responsible for severe pediatric respiratory infections worldwide. Identification of cellular factors able to restrict viral infection is one of the key strategies used to design new drugs against infection. Here, we report for the first time that the cellular protein BST2/Tetherin (a widely known host antiviral molecule) behaves as a restriction factor of RSV infection.
View Article and Find Full Text PDFEffect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
Lancet Child Adolesc Health
October 2024
Mathematical Modelling of Infectious Diseases Unit, Institut Pasteur, Université Paris Cité, CNRS UMR 2000, Paris, France. Electronic address:
Article Synopsis
- Respiratory syncytial virus (RSV) is a significant cause of hospitalizations and fatalities in infants globally, prompting France to start a national program administering nirsevimab, a monoclonal antibody treatment, to protect infants from RSV infections.
- A modeling study was conducted to evaluate the effectiveness of nirsevimab and estimate the number of RSV-related hospitalizations avoided in infants under 24 months during the 2023-24 season in France.
- The findings indicated that nirsevimab prevented approximately 5,800 RSV-associated hospitalizations for bronchiolitis in children under 24 months, with around 4,200 of these cases in infants aged 0-2 months.
Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.
N Engl J Med
December 2023
From the Centre for Neonatal and Paediatric Infections, St. George's, University of London, and the Department of Paediatrics, St. George's University Hospitals National Health Service (NHS) Foundation Trust, London (S.B.D.), the National Institute for Health Research Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, and the Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton (K.C., S.N.F.), the Liverpool Vaccine Group, Liverpool School of Tropical Medicine (A.M.C., H.C.H.), and Liverpool University Hospitals Foundation, NHS Trust (A.M.C.), Liverpool, Sanofi, Reading (C.T.F., N.C.V.), and the University of Nottingham Health Service, University of Nottingham, Nottingham (S.R.) - all in the United Kingdom; Université de Lille, INSERM, Centre Hospitalier Universitaire (CHU) de Lille, CIC-1403 INSERM-CHU, Lille (F.F.), the French Clinical Research Infrastructure Network-PEDSTART, Tours (F.F.), Centre Hospitalier Intercommunal de Créteil, and Association Clinique et Thérapeutique Infantile du Val-de-Marne, Créteil (R.C.), CHU Rouen, Department of Neonatal Pediatrics and Intensive Care and Neuropediatrics, Charles Nicolle University Hospital, Rouen (D.P.), Sanofi Vaccines, Lyon (M.B., R.N., S.W.), Sanofi Vaccines, Marcy L'Etoile (K.M.), Pediatric Intensive Care, Neonatal Medicine and Pediatric Emergency Department, Assistance Publique-Hôpitaux de Paris, Paris-Saclay University, Bicêtre Hospital, Le Kremlin-Bicêtre (P.T.), and the Institute of Integrative Biology of the Cell, Centre National de la Recherche Scientifique, Commissariat à l'Energie Atomique, Paris-Saclay University, Gif sur Yvette (P.T.) - all in France; Children's Hospital, Worms (M.K.), Pediatric Infectious Diseases, University Medicine, Mainz (M.K.), and Gemeinschaftspraxis für Kinder und Jugendmedizin, Tangstedter Landstrasse 77, Hamburg (F.K.) - all in Germany; Sanofi, Huipu Mansion, Beijing (J.J.); and Sanofi Vaccines, Bridgewater, NJ (M.R.).
Article Synopsis
- - A study was conducted to evaluate the safety and effectiveness of nirsevimab, a monoclonal antibody, in preventing hospitalizations due to respiratory syncytial virus (RSV) in healthy infants during their first RSV season.
- - Infants aged 12 months or younger who were born at least 29 weeks gestation were randomly assigned to receive either nirsevimab or standard care, with results showing that 0.3% in the nirsevimab group were hospitalized compared to 1.5% in the standard-care group, indicating an 83.2% efficacy for nirsevimab.
- - The study also found that severe cases of RSV were less common in the nirsevimab
Hardening of Respiratory Syncytial Virus Inclusion Bodies by Cyclopamine Proceeds through Perturbation of the Interactions of the M2-1 Protein with RNA and the P Protein.
Int J Mol Sci
September 2023
INRAE, Unité de Virologie et Immunologie Moléculaires (VIM), Université Paris-Saclay-Versailles St. Quentin, F-78350 Jouy-en-Josas, France.
Respiratory syncytial virus (RSV) RNA synthesis takes place in cytoplasmic viral factories also called inclusion bodies (IBs), which are membrane-less organelles concentrating the viral RNA polymerase complex. The assembly of IBs is driven by liquid-liquid phase separation promoted by interactions between the viral nucleoprotein N and the phosphoprotein P. We recently demonstrated that cyclopamine (CPM) inhibits RSV multiplication by disorganizing and hardening IBs.
View Article and Find Full Text PDFThe antitumor effect of oncolytic respiratory syncytial virus via the tumor necrosis factor-alpha induction and ROS-bax-mediated mechanisms.
BMC Cancer
August 2023
Department of Influenza and Other Respiratory Viruses, Pasteur Institute of Iran, Tehran, Iran.
Background: Cervical cancer represents one of the most prevalent cancers among women worldwide, particularly in low- and middle-income nations. Oncolytic viruses (OVs) can infect cancer cells selectively and lethally without harming normal cells. Respiratory syncytial virus (RSV) is an oncolytic virus for anticancer therapy because of its propensity to multiply within tumor cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!